TY - JOUR T1 - When can we safely return to normal? A novel method for identifying safe levels of NPIs in the context of COVID-19 vaccinations JF - medRxiv DO - 10.1101/2021.04.20.21255350 SP - 2021.04.20.21255350 AU - Gianluca Bianchin AU - Emiliano Dall’Anese AU - Jorge I. Poveda AU - Andrea G. Buchwald Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/21/2021.04.20.21255350.abstract N2 - Over the course of the COVID-19 pandemic, governing bodies and individuals have relied on a variety of non-pharmaceutical interventions (NPIs) to control the transmission of SARS-CoV-2, which posed an acute threat to individuals’ well-being and consistently impacted economic activities in many countries worldwide. NPIs have been implemented at varying levels of severity and in response to widely-divergent perspectives of risk tolerance. Now, concurrently with the introduction of multiple SARS-CoV-2 vaccines, the world looks optimistically to a “return to normality”. In this work, we propose a multi-disciplinary approach, combining transmission modeling with control and optimization theory, to examine how risk tolerance and vaccination rates will impact the safe return to normal behavior over the next few months. To this end, we consider a version of the Susceptible-Exposed-Infected-Recovered transmission model that accounts for hospitalizations, vaccinations, and loss of immunity. We then propose a novel control approach to calibrate the necessary level of NPIs at various geographical levels to guarantee that the number of hospitalizations does not exceed a given risk tolerance (i.e., a maximum allowable threshold). Our model and control objectives are calibrated and tailored for the state of Colorado, USA. Our results suggest that: (i) increasing risk tolerance can decrease the number of days required to discontinue all NPIs; (ii) increasing risk tolerance inherently increases COVID-19 deaths even in the context of vaccination; (iii) if the vaccination uptake in the population is 70% or less, then return to normal behavior within the next year may newly stress the healthcare system. Furthermore, by using a multi-region model accounting for travel, our simulations predict that: (iv) relaxation should take into account regional heterogeneity in transmission and travel; and (v) premature relaxation of NPIs, even if restricted only to low-density regions, will lead to exceeding hospitalization limits even when highly-populated regions implement full-closures. Although the simulations are performed for the state of Colorado, the proposed model of transmission and control methods are applicable to any area worldwide and can be utilized at any geographical granularity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the AB Nexus seed grant from the University of Colorado.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No data was directly collected for this study; all data used for the purpose of this study were aggregate metrics published elsewhere and as properly referenced in the manuscript. Approval was received to use all the data included the present work as detailed in the Acknowledgements section. The EMResource data on hospital census is publicly available on the CDPHE website (https://covid19.colorado.gov/data). The dataset used in this study is publicly available at https://docs.safegraph.com/docs/ and approval was received from Safegraph to use the data for the purpose of academic publishing. There was no registration ID or approval code necessary. All data sources have been acknowledged in the acknowledgment section. The study did not involve human or animal subjects. The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.All funding resources have been referenced in the funding section of the manuscript.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. ER -